Review
Open access
Jun 2026
Endothelin antagonism: a new era for resistant hypertension
In the phase 3 PRECISION trial, aprocitentan significantly reduced blood pressure in patients with resistant hypertension, with additional reductions in albuminuria, and may provide benefits beyond blood pressure reduction.
G. Chapman, D. Pugh, N. Dhaun
· Clinical Kidney Journal · 0 citations